Patrick W Sullivan1, Vahram Ghushchyan2, Prakash Navaratnam3, Howard S Friedman3, Abhishek Kavati4, Benjamin Ortiz4, Bob Lanier5. 1. Department of Pharmacy Practice, Regis University School of Pharmacy, Denver, Colorado. Electronic address: psulliva@regis.edu. 2. Department of Clinical Pharmacy, University of Colorado, Denver, Colorado; College of Business and Economics, American University of Armenia, Yerevan, Armenia. 3. DataMed Solutions LLC, New York, New York. 4. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey. 5. Department of Pediatrics, University of North Texas, Fort Worth, Texas.
Abstract
BACKGROUND: Recent research has quantified the national health care resource use (HCRU) and health care expenditure (HCE) burden associated with adult asthma; however, estimates specific to school-aged children are more than 2 decades old. OBJECTIVE: To estimate the national HCRU and HCEs attributable to asthma among school-aged children in the United States. METHODS: This was a cross-sectional retrospective analysis of school-aged children (aged 6-17 years) in the nationally representative 2007-2013 Medical Expenditure Panel Survey. All-cause HCRU and HCEs of school-aged children with asthma were compared with school-aged children without asthma, controlling for sociodemographics and comorbidities. HCRU encounters included emergency department (ED) and outpatient visits, hospitalizations, and prescriptions. Expenditures included total, medical, ED, inpatient, outpatient, and pharmacy. Negative binomial regression analyses were used for HCRU and Heckman selection with logarithmic transformation, and smearing retransformation was used for HCEs. RESULTS: There were 44,320 school-aged children of whom 5,890 had asthma. Children with asthma incurred a higher rate of all-cause annual ED visits (incidence rate ratio [IRR], 1.5; P < .001), hospitalizations (IRR, 1.4; P < .05), outpatient visits (IRR, 1.4; P < .001), and prescription drugs (IRR, 3.3; P < .001) compared with school-aged children without asthma. They incurred US$847 (2015 dollars) more annually in all-cause expenditures (P < .001). Private insurance and Medicaid paid the largest share of expenditures. Pharmacy and outpatient costs represented the largest proportion of total expenditures. On the basis of the nationally representative Medical Expenditure Panel Survey sample weights from 2013, the total annual HCEs attributable to asthma for school-aged children in the United States was US$5.92 billion (2015 dollars). CONCLUSION: Childhood asthma continues to represent a prevalent and significant clinical and economic burden in the United States. More aggressive treatment and asthma management programs are needed to address this national financial and resource burden.
BACKGROUND: Recent research has quantified the national health care resource use (HCRU) and health care expenditure (HCE) burden associated with adult asthma; however, estimates specific to school-aged children are more than 2 decades old. OBJECTIVE: To estimate the national HCRU and HCEs attributable to asthma among school-aged children in the United States. METHODS: This was a cross-sectional retrospective analysis of school-aged children (aged 6-17 years) in the nationally representative 2007-2013 Medical Expenditure Panel Survey. All-cause HCRU and HCEs of school-aged children with asthma were compared with school-aged children without asthma, controlling for sociodemographics and comorbidities. HCRU encounters included emergency department (ED) and outpatient visits, hospitalizations, and prescriptions. Expenditures included total, medical, ED, inpatient, outpatient, and pharmacy. Negative binomial regression analyses were used for HCRU and Heckman selection with logarithmic transformation, and smearing retransformation was used for HCEs. RESULTS: There were 44,320 school-aged children of whom 5,890 had asthma. Children with asthma incurred a higher rate of all-cause annual ED visits (incidence rate ratio [IRR], 1.5; P < .001), hospitalizations (IRR, 1.4; P < .05), outpatient visits (IRR, 1.4; P < .001), and prescription drugs (IRR, 3.3; P < .001) compared with school-aged children without asthma. They incurred US$847 (2015 dollars) more annually in all-cause expenditures (P < .001). Private insurance and Medicaid paid the largest share of expenditures. Pharmacy and outpatient costs represented the largest proportion of total expenditures. On the basis of the nationally representative Medical Expenditure Panel Survey sample weights from 2013, the total annual HCEs attributable to asthma for school-aged children in the United States was US$5.92 billion (2015 dollars). CONCLUSION: Childhood asthma continues to represent a prevalent and significant clinical and economic burden in the United States. More aggressive treatment and asthma management programs are needed to address this national financial and resource burden.
Authors: Yiping Liu; Yury A Bochkov; Jens C Eickhoff; Tianchen Hu; Nicholas A Zumwalde; Jin Wen Tan; Christopher Lopez; Paul S Fichtinger; Thiruchelvi R Reddy; Katherine A Overmyer; Jennifer E Gumperz; Joshua Coon; Sameer K Mathur; James E Gern; Judith A Smith Journal: Am J Respir Cell Mol Biol Date: 2020-06 Impact factor: 6.914
Authors: Jennifer A Lucas; Miguel Marino; Katie Fankhauser; Steffani R Bailey; David Ezekiel-Herrera; Jorge Kaufmann; Stuart Cowburn; Shakira F Suglia; Andrew Bazemore; Jon Puro; John Heintzman Journal: J Asthma Date: 2019-08-22 Impact factor: 2.515
Authors: Christina Crabtree-Ide; Denise F Lillvis; Jing Nie; Maria Fagnano; Reynaldo S Tajon; Paul Tremblay; Jill S Halterman; Katia Noyes Journal: Popul Health Manag Date: 2021-05-14 Impact factor: 2.459
Authors: Evin J Howard; Stephen J Vesper; Barbara J Guthrie; Carter R Petty; Valeria A Ramdin; William J Sheehan; Jonathan M Gaffin; Perdita Permaul; Peggy S Lai; Lisa M Bartnikas; Amparito Cunningham; Marissa Hauptman; Diane R Gold; Sachin N Baxi; Wanda Phipatanakul Journal: J Allergy Clin Immunol Pract Date: 2020-10-19
Authors: Jean-Marie Bruzzese; Maureen George; Jianfang Liu; David Evans; Sylvie Naar; Melissa E DeRosier; James M Thomas Journal: Patient Educ Couns Date: 2020-09-15